H.-J. Schmoll scite author profile

No statistically significant differences in treatment efficacy were detected between 20 Gy IF radiotherapy and 1X (COPP + ABVD) chemotherapy following CR after six cycles of alternating chemotherapy in patients with advanced-stage HD. However, limited observations in a non-randomized cohort indicate that patients without consolidation treatment of CR after 6 cycles of chemotherapy may have an elevated risk of relapse.

show abstract

295 Capecitabine plus irinotecan (CAPIRI) vs capecitabine plus oxaliplatin (CAPOX) as first-line therapy of advanced colorectal cancer (ACRC): updated results of a randomized phase II trial

Grothey¹,

Jordan²,

Kellner³

et al. 2003

European Journal of Cancer Supplements

View full text Add to dashboard Cite

Phase II Trial of Capecitabine/Irinotecan and Capecitabine/Oxaliplatin in Advanced Gastrointestinal Cancers

Jordan¹,

Kellner²,

Kegel³

et al. 2004

Clinical Colorectal Cancer

View full text Add to dashboard Cite

OC-0250: First results of the PETACC-6 randomized phase III trial in locally advanced rectal cancer

Haustermans¹,

Schmoll²,

Price³

et al. 2014

Radiotherapy and Oncology

View full text Add to dashboard Cite

The integration of targeted agents into systemic therapy of metastatic colorectal cancer

Arnold¹,

Siewczynski²,

Schmoll³

2006

Annals of Oncology

View full text Add to dashboard Cite

12 3 4 5

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

H.-J. Schmoll

Observations on experimental marginal periodontitis in rats

Randomized Phase III Study of High-Dose Fluorouracil Given As a Weekly 24-Hour Infusion With or Without Leucovorin Versus Bolus Fluorouracil Plus Leucovorin in Advanced Colorectal Cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952

Phase III trial of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (MAYO) vs. weekly oxaliplatin (OXA) plus high dose 24h 5-FU infusion/FA in patients with advanced colorectal cancer (CRC)

Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advanced Hodgkin's disease

295 Capecitabine plus irinotecan (CAPIRI) vs capecitabine plus oxaliplatin (CAPOX) as first-line therapy of advanced colorectal cancer (ACRC): updated results of a randomized phase II trial

Phase II Trial of Capecitabine/Irinotecan and Capecitabine/Oxaliplatin in Advanced Gastrointestinal Cancers

OC-0250: First results of the PETACC-6 randomized phase III trial in locally advanced rectal cancer

The integration of targeted agents into systemic therapy of metastatic colorectal cancer

Contact Info

Product

Resources

About